Checkpoint therapeutics, inc. (CKPT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'14
Cash Flows from Operating Activities:
Net loss

-22,105

-24,714

-27,507

-31,645

-33,492

-36,367

-30,666

-27,250

-27,059

-22,677

-25,082

-24,282

-23,239

-22,461

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,962

3,121

2,102

2,396

1,655

1,994

1,182

965

3,275

3,117

5,487

5,337

3,758

3,867

0

0

0

0

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common shares - Founders Agreement

729

738

198

280

183

815

815

641

641

0

0

0

0

14

0

0

0

0

Common shares issuable - Founders Agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common shares for license expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

324

0

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-311

-509

-456

439

-158

-485

-696

-346

1,004

1,786

1,868

870

214

-100

0

0

0

0

Other receivables - related party

895

-1,506

275

924

-267

1,201

-345

-716

-349

-490

-224

-406

611

756

0

0

0

0

Accounts payable and accrued expenses

-1,222

-5,043

-971

1,359

680

6,721

2,939

2,548

3,222

2,699

1,384

467

2,716

1,883

0

0

0

0

Net cash used in operating activities

-17,710

-21,373

-24,249

-27,225

-28,801

-25,805

-22,393

-19,738

-17,880

-15,461

0

0

0

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Purchase of research and development licenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cash Flows from Financing Activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from note payable, net of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

2,792

0

0

0

0

Proceeds from issuance of common stock, net of offering costs of $2,195 and $0, respectively

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Cash received for issuance of founders shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

0

0

0

0

Offering costs for the issuance of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

Issuance of common shares - At-the-market offering

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

Offering costs for the issuance of common shares - At-the-market offering

-188

-198

-195

-349

-244

-234

0

0

0

-

-

-

-

-

-

-

-

-

Offering costs for the issuance of common shares - Public offering

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

25,044

25,455

7,709

12,126

8,085

28,575

28,575

20,817

20,845

0

0

0

0

-

-

-

-

-

Net decrease in cash and cash equivalents

7,334

4,082

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

2,565

-15,861

-15,936

-15,023

-13,671

-15,332

0

0

0

0

Supplemental disclosure of noncash investing and financing activities:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Debt discount associated with warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common shares - Founders Agreement

0

1,748

1,748

1,748

1,748

2,296

2,296

2,296

2,296

3,919

3,919

3,919

3,919

3,024

0

0

0

0